Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/James Shin
DB
James Shin
Deutsche Bank
Wall Street Analyst
★★★☆☆
#1053
on 13Foresight · ranked by our own returns
65%
Success Rate
+17.9%
Average Return
11 of 17 calls profitable · -0.1% vs benchmark
📈 Across the calls we could measure, roughly 65% of James Shin's ratings turned a profit when each position was held for 1 year — averaging +17.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

10 Buy 2 Hold 0 Sell
James's Stock Coverage 19 ratings · 2026-06-21
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
LLY
Eli Lilly & Co
 May 07, 2026 BUY Strong Buy
-10.5% avg upside
47 analysts
$1285.00
17.01% Upside
 +12.9%
AAPG
Ascentage Pharma Group International Unsponsored ADR
 Apr 24, 2026 BUY Strong Buy
+156.7% avg upside
10 analysts
$40.00
133.69% Upside
 -12.3%
STRO
Sutro Biopharma
 Mar 25, 2026 BUY Strong Buy
+31.6% avg upside
20 analysts
$55.00
85.64% Upside
 +22.6%
LEGN
Legend Biotech
 Mar 09, 2026 BUY Strong Buy
+140.3% avg upside
27 analysts
$60.00
114.77% Upside
 +87.4%
MRK
Merck & Company
 Feb 13, 2026 BUY Strong Buy
+10.7% avg upside
43 analysts
$150.00
31.81% Upside
 -3.5%
ABBV
AbbVie
 Sep 15, 2025 HOLD Buy
+2.9% avg upside
43 analysts
$204.00
5.81% Downside
 +4.1%
GILD
Gilead Sciences
 Aug 11, 2025 BUY Strong Buy
-4.8% avg upside
66 analysts
$135.00
9.02% Upside
 +5.4%
IMTX
Immatics
 May 28, 2025 BUY Strong Buy
+86.8% avg upside
15 analysts
$10.00
2.17% Upside
 +111.5%
IMCR
Immunocore Holdings
 May 27, 2025 BUY Strong Buy
+124.3% avg upside
22 analysts
$65.00
127.35% Upside
 -12.4%
BMY
Bristol-Myers Squibb
 Feb 10, 2025 HOLD Buy
+9.1% avg upside
42 analysts
$53.00
1.78% Downside
 +15.1%
AMGN
Amgen
 Nov 26, 2024 HOLD Buy
-11.6% avg upside
57 analysts
$305.00
9.56% Downside
 +27.1%
INCY
Incyte
 Sep 19, 2024 HOLD Strong Buy
+1.0% avg upside
47 analysts
$61.00
37.95% Downside
 +29.5%
DE:LXS
LANXESS
 Aug 12, 2024 BUY Buy
+105.8% avg upside
12 analysts
$27.00
56.27% Upside
 ·
AUTL
Autolus Therapeutics
 Aug 09, 2024 BUY Strong Buy
+605.8% avg upside
16 analysts
$10.00
562.22% Upside
 -36.5%
REGN
Regeneron
 Aug 01, 2024 HOLD Strong Buy
+26.9% avg upside
57 analysts
$870.00
42.70% Upside
 -48.7%
TCRT
Alaunos Therapeutics
 Mar 08, 2023 BUY Buy
+604.3% avg upside
13 analysts
$45.00
1993.00% Upside
 -78.9%
ZYME
Zymeworks
 Mar 08, 2023 BUY Strong Buy
+40.3% avg upside
25 analysts
$12.00
48.05% Downside
 +43.0%
IOVA
Iovance Biotherapeutics
 Mar 05, 2023 HOLD Strong Buy
+225.8% avg upside
24 analysts
$11.00
181.40% Upside
 +137.6%
AFMDQ
Affimed
 Dec 12, 2022 BUY Buy
+12648900.0% avg upside
15 analysts
$7.00
6999900.02% Upside
 ·
🔒 14 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
James Shin — Frequently Asked Questions
How accurate are James Shin's stock ratings?
Based on the calls 13Foresight could measure, about 65% of James's ratings were profitable over a one-year hold, with an average return of +17.9% per rating, or -0.1% versus the S&P 500. We score every analyst the same way, from historical prices.
How is James ranked on 13Foresight?
James Shin is currently ranked #1053 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does James cover?
James most recently has ratings on LLY, AAPG, STRO, LEGN, MRK, ABBV, GILD, IMTX, IMCR, BMY, AMGN, INCY and 7 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.